Sarana Meditama Metropolitan Tbk PT
Sarana Meditama Metropolitan Tbk PT has a liquidity position that is characterized by a current ratio of 0.9, indicating that its current liabilities exceed its current assets. The company's cash and equivalents amount to 41,000,000,000, which is significantly lower than its long-term debt of 974,054,110,770, suggesting a potential liquidity risk. The return on equity is 0.0004, and the return on assets is 0.0003, both of which are very low, indicating that the company is not generating significant returns for its shareholders or assets. The company's profitability is reflected in its net income of 14,304,565,000, but this is relatively small compared to its total revenue of 435,772,363,980. The operating income of 26,411,536,610 is also modest, and the gross profit of 146,508,345,500 suggests that the company is not achieving high margins. These metrics are below the industry norms, indicating that the company may be struggling to maintain competitive profitability. The company's revenue is primarily concentrated in the healthcare sector, with no significant diversification across segments or geographic regions. This concentration could pose a risk if the healthcare sector experiences a downturn. The company's exposure to different geographic markets is not disclosed, but the lack of segment data suggests that it may not have a diversified revenue base. The company's growth trajectory is uncertain, as there is no clear indication of future revenue growth. The capital expenditure of -78,015,705,100 indicates that the company is not investing heavily in new projects or infrastructure, which could limit its growth potential. The free cash flow is negative at -12,172,122,339.9999, suggesting that the company is not generating enough cash to fund its operations and investments. The risk assessment indicates that the company has a medium liquidity risk and a low dilution risk. The key flag of net cash being negative after subtracting total debt highlights the company's financial vulnerability. The dilution potential is low, but the company's financial structure may require additional financing in the future, which could lead to dilution. Recent events and filings do not provide specific details about the company's operations or financial performance. The analyst estimate for the last actual revenue is 952,082,110,000 IDR, which is significantly higher than the reported revenue, suggesting potential discrepancies or unverified data.
Business. Sarana Meditama Metropolitan Tbk PT operates in the healthcare facilities and services industry, providing pharmaceuticals and related healthcare services.
Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a classification confidence of 0.92.
- The company has a low return on equity and assets, indicating poor profitability.
- The liquidity position is weak, with a current ratio below 1 and significant long-term debt.
- The company's revenue is not diversified, posing a risk if the healthcare sector declines.
- The capital expenditure is negative, suggesting a lack of investment in growth.
- The company's free cash flow is negative, indicating insufficient cash generation.
- # RATIONALES
- **margin_outlook_rationale**: The company's gross profit margin is moderate, but the operating and net profit margins are low, indicating potential cost management issues.
- **rd_outlook_rationale**: There is no specific information provided about the company's research and development activities or their impact on future growth.
- Net cash is negative after subtracting total debt.